HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00095810

Aripiprazole safety for psychosis in Parkinson’s disease

About this titleRead the official source — NCT00095810
Medication studyAges 50+United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 50 years.

What did participation involve?

The study group receives aripiprazole as a study medication.

Listed locations
AlbanySee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2003
Recruitment status
Completed
Enrollment listed in the registry
50
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
Over 50 Years
Official registry ID
NCT00095810
Official title
Show the full official title

An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Albany

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including aripiprazole.

Who was this study for?

Listed age limits: from 50 years.

Want to explore more studies?

Explore studies